Literature DB >> 7698133

Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?

J M Good1, P Nihoyannopoulos, M A Ghatei, D Crossman, S R Bloom, P Clark, C M Oakley, J G Cleland.   

Abstract

Endothelin is a powerful vasoconstrictor that may be partly responsible for the increases in venous and arterial tone characteristic of heart failure. The release of endothelin from endothelial cells in culture is stimulated by angiotensin II. We investigated the relationship between plasma concentrations of immuno reactive endothelin-1 and angiotensin II in 25 patients with heart failure and eight with ischaemic heart disease but normal left ventricular function. Plasma concentrations of endothelin and angiotensin II were correlated (Spearman rank correlation coefficient of 0.72; P < 0.0001) in patients with heart disease. Plasma concentrations of angiotensin II and endothelin were higher in those patients with heart failure. Angiotensin II was infused over a 3 h period in eight healthy volunteers. Infusion of angiotensin II increased plasma concentrations of angiotensin II to levels greater than those usually found in patients with severe heart failure but induced only a modest rise in plasma concentrations of immunoreactive endothelin-1 (0.77 +/- 0.16 to 1.03 +/- 0.03 pmol.l-1, P < 0.02). Increased plasma concentrations of angiotensin II and endothelin-1 both appear to reflect the presence and severity of heart failure. Although a significant correlation exists between plasma concentrations of angiotensin II and endothelin in patients with heart failure, the relationship may not be causal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698133     DOI: 10.1093/oxfordjournals.eurheartj.a060446

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

4.  Endothelin in heart failure: a promising therapeutic target?

Authors:  M P Love; J J McMurray
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

5.  Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure.

Authors:  O Grenier; F Pousset; R Isnard; H Kalotka; A Carayon; G Maistre; P Lechat; C Guerot; D Thomas; M Komajda
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

6.  CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis.

Authors:  Toshimitsu Okuda; Norimasa Yoshida; Tomohisa Takagi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Yuji Naito; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

Review 7.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

Review 8.  Role of antithrombotic agents in heart failure.

Authors:  John G F Cleland; Saqib Mumtaz; Luca Cecchini
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.